Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 11c ; offers Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.18, $0.11 better than the analyst estimate of $1.07. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $59.11 million.

GUIDANCE:

Eagle Pharmaceuticals sees Q3 2023 EPS of $4.40-$4.70, versus the consensus of $4.48.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• H.B. Fuller makes £715M cash offer to acquire Advanced Medical Solutions
• Goldman Sachs Upgrades Primoris Services Corporation (PRIM) to Neutral